News & Events
22 Dec 2011 Invitation to apply to become an independent assessor of group 2 driving licence applicants
People with diabetes treated with insulin are now able to apply for any group two driving licence . The process of assessment will be
1) A driver wishing to apply for a Group 2 licence will first have to fill out a self-declaration form and consent.
2)Information will be obtained from their clinician (Consultant or GP). This will generate a fee that will be paid by the DVLA. Applicants who clearly fail on the criteria will not proceed further. Applicants whose application is rejected can reapply in the future if their circumstances change.
3) The DVLA will refer applicants who meet the criteria for an independent assessment by a consultant diabetologist, who will report to DVLA. A fee will be paid by the DVLA.
4) The final decision as to fitness to drive a class 2 vehicle will lie with the DVLA.
5) There is a right of appeal to a local magistrates or sheriffs court.
Although local diabetologists known to the patient may be involved at stage 2, the DVLA requires a rigorous independent assessment at stage 3. ABCD has agreed to assist the DVLA in identifying assessors for stage 3 (the independent assessment).Discussions are proceeding to set up a training programme for any consultant diabetologist holding a CST wishing to be an independent assessor. Meanwhile in view of the need to establish the assessment process without delay, consultants holding a CST in diabetes who feel that they have appropriate experience are invited to apply to the DVLA using the attached form.
Click here to download the application form.
Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies
Metformin use was associated with a decreased risk of AF in patients with type 2 DM who were not using other anti-diabetic medication, probably via attenuation of atrial cell tachycardia-induced myolysis and oxidative stress (Cardiovascular Diabetology)
The predictive role of markers of Inflammation and endothelial dysfunction on the course of diabetic retinopathy in Type 1 Diabetes
High levels of sE-selectin and PAI-1 are associated with the development of retinopathy in patients with uncomplicated type 1 diabetes (Diabetes and Its Complications)
Rhe first zinc transporter 8 autoantibody (ZnT8Ab) test that can help determine if a person has type 1 diabetes and not another type of diabetes (U.S. Food and Drug Administration)
Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders
Our results show that metformin may reduce cancer incidence and mortality in patients with diabetes However, the reduction seems to be of modest magnitude and not affecting all populations equally (Cancer Prevention Research)
The three-year research collaboration will develop small molecule candidates from their respective portfolios (Mitsubishi Tanabe)